Related Experiment Video

Updated: Jul 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent

J Lin1, X Jin, C Page

  • 1Department of Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA. linjia@umich.edu

Cancer Research
|November 4, 2000
PubMed

Insights

An engineered p53 variant, p53 14/19, effectively suppresses cancer cell growth, even when mdm2 (murine double minute 2) inhibits wild-type p53. This modified tumor suppressor shows therapeutic promise for cancers with high mdm2 levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Wild-type p53's tumor-suppressive function is often inhibited by the mdm2 oncogene product.
  • Cancer cells frequently exhibit amplified mdm2, leading to p53 inactivation and uncontrolled proliferation.

Purpose of the Study:

  • To evaluate the growth suppression and antioncogenic activities of p53 14/19, a novel p53 variant designed to resist mdm2 inhibition.
  • To determine the therapeutic potential of p53 14/19 in cancers characterized by high mdm2 expression.

Main Methods:

  • Assessed p53 14/19's antiproliferative effects on cancer cells via DNA transfection and adenovirus-mediated gene transfer.
  • Utilized a rat embryo fibroblast cotransformation assay to examine p53 14/19's antioncogenic potency against various oncogenes (ras, mdm2, c-myc, E1A, E7).

Main Results:

  • p53 14/19 efficiently suppressed the growth of cancer cells with amplified mdm2, unlike wild-type p53.
  • p53 14/19 demonstrated potent inhibition of oncogenic transformation mediated by ras plus mdm2, as well as other oncogenes.
  • The variant also inhibited cancer cell lines with low mdm2 levels comparably to wild-type p53.

Conclusions:

  • p53 14/19 overcomes mdm2-mediated inhibition, offering a potential therapeutic strategy for cancers overexpressing mdm2.
  • The engineered p53 variant exhibits significant antioncogenic activity, suggesting its promise as a novel cancer therapeutic agent.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...